The precise identification of tumor boundaries during radical prostatectomy remains a major clinical challenge. As positive surgical margins occur in 15–40% of prostate cancer cases, the risk of postoperative recurrence and functional impairment is significantly increased.
Researchers have created an artificial intelligence model that can identify which mutations in human proteins are most likely to cause disease, even when those mutations have never been seen before in any person.
Patients with the deadliest form of brain cancer, glioblastoma, who received MRI-guided focused ultrasound with standard-of-care chemotherapy had a nearly 40% increase in overall survival in a landmark trial of 34 patients led by University of Maryland School of Medicine (UMSOM) researchers.
CeriBell (Nasdaq:CBLL) announced today that it received FDA 510(k) clearance for its next-generation Clarity algorithm.
Researchers at Washington University School of Medicine in St. Louis, along with collaborators at Northwestern University, have developed a noninvasive approach to treat one of the most aggressive and deadly brain cancers.
A new study has shown that a clinical tool developed by the University of Liverpool and The Walton Center can accurately predict whether the most common type of brain tumor will grow or cause symptoms, helping doctors and patients make better-informed decisions about care.
A patented RNA-based cocktail developed at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has emerged as a promising active agent against tumors of the central nervous system, such as glioblastoma.
Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger RNA—best known for being used in COVID-19 vaccines—in the hopes of finding a breakthrough treatment for a particularly deadly cancer.
Researchers at the Eye Genetics Research Unit at Children’s Medical Research Institute (CMRI) are the first in the world to use stem cells to study one of the genetic causes of Leber Congenital Amaurosis (LCA)—a rare condition that causes severe vision loss in babies and young children.
The immune system plays a crucial role in fighting tumors and metastases. Consequently, it is decisive to conduct cancer research in mouse models with an immune system that is as natural as possible—which is easier said than done.